In conclusion, SP-D and KL-6 are useful biomarkers for differentiating patients with honeycombing on HRCT into the stable and progressive stages, which would inform clinical implication for IPF. This evidence concerns the gene MUC1 and idiopathic pulmonary fibrosis.